Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

NCT04894435 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

669

Enrollment

NETWORK

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: mRNA-1273 SARS-CoV-2 vaccine
BIOLOGICAL: BNT162b2
BIOLOGICAL: ChAdOx1-S [recombinant]
OTHER: 0, 28 day schedule
OTHER: 0, 112 day schedule
BIOLOGICAL: Covifenz

Sponsor

Canadian Immunization Research Network

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]